In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Return Of The Renaissance Man: Industry Hopping Entrepreneurship

Executive Summary

Lars Christian Wilde, a 2021 In Vivo Rising Leader, is president and co-founder of Compass Pathways, a psychedelic medicines company developing psilocybin for mental health disorders. An entrepreneur who began his career in finance before launching an athletics company, two cooking supply companies and an investment fund, among other achievements, Wilde describes himself as ‘a generalist who surrounds himself with amazing people.’

You may also be interested in...



Translating Psychedelic Experiences Into Targeted Health Outcomes: Optimism And Concern

A panel of executives, academics and experts discussed the potential for psychedelic therapies, such as MDMA and psilocybin, to revolutionize behavioral health in a recent Demy Colton virtual salon. But with nearly 50 publicly traded companies now developing psychedelics, some panelists expressed concern about a rush to market, and “competition and domination” harshening the buzz.

Using Data To Improve Rare Disease Diagnosis And Treatment

A deeper understanding of rare diseases – how they differ across geographies and ethnicities, or which genes and biomarkers are most useful targets for new treatments – can help to accelerate and de-risk clinical trials. On the commercial front, patient data and insights could mean the difference between a category leader and a failure.

New PBM Models Aim To Lower Out-Of-Pocket Costs

Start-up pharmacy benefit managers such as Capital Rx and Evio hope to shake up the traditional PBM service model with increased drug price transparency, aggregated real-world data and outcomes-based contracting. The big three PBMs which dominate the market represent a formidable challenge.

Topics

UsernamePublicRestriction

Register

IV124867

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel